Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COLLEGIUM PHARMACEUTICAL, INC
Report date March 04, 2025 · Filed March 06, 2025
Section 16 reporting ended · disclosed 2025-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 108,137 |
Ending reported balance
After 2025-03-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-04 · Exercise / conversion · Acquired 40,000 · Balance 194,204 Row 2 · 2025-03-04 · Sale · Disposed 40,000 · Balance 154,204 F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Row 3 · 2025-03-05 · Sale · Disposed 20,000 · Balance 134,204 F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive. Row 4 · 2025-03-06 · Sale · Disposed 26,067 · Balance 108,137 F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $24.03 · Expires 2028-04-04 | Direct | 0 |
Reported balance
After 2025-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-04 · Exercise / conversion · Disposed 40,000 · Balance 0 F4: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive.
F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive.
F4: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2025 Filed Mar 6, 2025 18:48 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 26,067 | $28.50 | $742,945.99 |
DisclosureSEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,137 F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.50 to $28.58, inclusive. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 18:48 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 20,000 | $28.03 | $560,528.00 |
DisclosureSEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,204 F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.18, inclusive. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 18:48 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 40,000 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001062993-25-004776 · form4.xml · derivative · entry 5 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2028-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 18:48 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 40,000 | $28.08 | $1,123,160.00 |
DisclosureSEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,204 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.00 to $28.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 18:48 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 40,000 | $24.03 | $961,200.00 |
DisclosureSEC source: 0001062993-25-004776 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 25,149 | $30.52 | $767,547.48 |
DisclosureSEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,204 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 9,826 | $30.52 | $299,889.52 |
DisclosureSEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,353 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 29,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,179 F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 29,030 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 40,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002175 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,149 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 27,500 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-25-000761 · form4.xml · derivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,100 | $33.64 | $205,220.47 |
DisclosureSEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.42 to $33.41, inclusive. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 21,400 | $32.87 | $703,407.30 |
DisclosureSEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,284 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.43 to $33.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:12 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 27,500 | $21.34 | $586,850.00 |
DisclosureSEC source: 0001062993-25-000761 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024. Read SEC document |
| September 06, 2024 Filed Sep 6, 2024 17:52 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 977 | $37.46 | $36,594.12 |
DisclosureSEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,184 F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.455 to $37.4592, inclusive. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 17:52 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,400 | $39.14 | $93,941.04 |
DisclosureSEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,161 F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.01 to $39.20, inclusive. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 17:52 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 16,848 | $38.18 | $643,256.64 |
DisclosureSEC source: 0001062993-24-016277 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,561 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 700 | $33.22 | $23,254.00 |
DisclosureSEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,409 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.19 to $33.31, inclusive. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 24,300 | $32.55 | $790,926.12 |
DisclosureSEC source: 0001062993-24-011979 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,109 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.18 to $33.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 10,610 | $33.70 | $357,557.00 |
DisclosureSEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,409 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 21,146 | $33.70 | $712,620.20 |
DisclosureSEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,019 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 33,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,165 F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 33,247 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 16:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 43,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003167 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,918 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 16:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 25,600 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001062993-23-021604 · form4.xml · derivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,600 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 16:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,600 | $25.78 | $660,014.08 |
DisclosureSEC source: 0001062993-23-021604 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,518 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.76 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 16:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 25,600 | $15.90 | $407,040.00 |
DisclosureSEC source: 0001062993-23-021604 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 16:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,363 | $22.53 | $30,715.07 |
DisclosureSEC source: 0001062993-23-014095 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,518 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.39 to $22.59, inclusive. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 16:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 16,621 | $21.65 | $359,917.78 |
DisclosureSEC source: 0001062993-23-014095 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,881 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.26 to $22.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 21,811 | $26.88 | $586,279.68 |
DisclosureSEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 5 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,502 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2022. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 7,755 | $26.75 | $207,446.25 |
DisclosureSEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,313 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 16,291 | $26.75 | $435,784.25 |
DisclosureSEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,068 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,739 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,359 F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 25,739 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 17:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 48,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-003479 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,620 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 16:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 38,589 | $18.07 | $697,303.23 |
DisclosureSEC source: 0001062993-22-019618 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2022 and amended on August 15, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 16:34 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 300 | $20.01 | $6,003.00 |
DisclosureSEC source: 0001062993-22-017994 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 16:03 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 734 | $18.99 | $13,938.66 |
DisclosureSEC source: 0001062993-22-008131 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,384 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,212 | $17.63 | $74,257.56 |
DisclosureSEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,118 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 6,967 | $17.63 | $122,828.21 |
DisclosureSEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,330 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 14,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,297 F2 · price: On February 10, 2022, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 14,341 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 18:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 56,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004319 · form4.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,956 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2023, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 16:03 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 734 | $19.67 | $14,437.78 |
DisclosureSEC source: 0001879789-21-000003 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,256 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,000 | $22.77 | $159,390.00 |
DisclosureSEC source: 0001192482-21-000419 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,990 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 16:07 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 734 | $24.69 | $18,122.46 |
DisclosureSEC source: 0001192482-21-000251 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,990 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 3,695 | $25.95 | $95,885.25 |
DisclosureSEC source: 0001192482-21-000150 · edgar.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,724 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,163 | $25.95 | $56,129.85 |
DisclosureSEC source: 0001192482-21-000150 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,419 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 16:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,081 | $24.45 | $148,680.45 |
DisclosureSEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,582 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 16:05 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,081 | $24.45 | $148,680.45 |
DisclosureSEC source: 0001192482-21-000094 · edgar.xml · nonDerivative · entry 3 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,582 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 129,600 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001192482-21-000085 · edgar.xml · derivative · entry 4 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,600 Underlying: Common Stock · 129,600 shares Expires 2031-01-19 F4 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 6,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,663 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000085 · edgar.xml · nonDerivative · entry 1 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,891 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 16:05 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 6,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000094 · edgar.xml · nonDerivative · entry 2 Kuhlmann Shirley R. · CIK 0001734919 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,663 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.